VivoSeq
Dermatology

Onychomycosis

0

Pipeline Programs

5

Active Trials

19

Companies Involved

Onychomycosis is an early-stage landscape with 0 programs across 19 companies. The most active players are Pfizer, Celtic Pharma Development Services, Nitric BioTherapeutics, Inc.

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

94/100

Attrition Rate

4/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

49

clinical trials

Completed31 · 63%
Unknown status11 · 22%
Active, not recruiting3 · 6%
Terminated2 · 4%
Not yet recruiting2 · 4%

Trial Activity

49 trials

Study of Different Doses of a Novel Treatment for Onychomycosis
Completed·Pfizer logoPfizer·Phase 2·NCT00679965·159 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)